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There is an acute dearth of therapeutic interventions against visceral leishmaniasis that is required to
restore an established defective cell-mediated immune response. Hence, formulation of effective immunother-
apy requires the use of dominant antigen(s) targeted to elicit a specific antiparasitic cellular immune response.
We implemented hybrid cell vaccination therapy in Leishmania donovani-infected BALB/c mice by electrofusing
dominant Leishmania antigen kinetoplastid membrane protein 11 (KMP-11)-transfected bone marrow-derived
macrophages from BALB/c mice with allogeneic bone marrow-derived dendritic cells from C57BL/6 mice.
Hybrid cell vaccine (HCV) cleared the splenic and hepatic parasite burden, eliciting KMP-11-specific major
histocompatibility complex class I-restricted CD8 cytotoxic T-lymphocyte (CTL) responses. Moreover, splenic
lymphocytes of HCV-treated mice not only showed the enhancement of gamma interferon but also marked an
elevated expression of the Th2 cytokines interleukin-4 (IL-4) and IL-13 at both transcriptional and transla-
tional levels. On the other hand, IL-10 production from splenic T cells was markedly suppressed as a result
of HCV therapy. CD8 T-cell depletion completely abrogated HCV-mediated immunity and the anti-KMP-11
CTL response. Interestingly, CD8 T-cell depletion completely abrogated HCV-induced immunity, resulting in
a marked increase of IL-10 but not of IL-4 and IL-13. The present study reports the first implementation of
HCV immunotherapy in an infectious disease model, establishing strong antigen-specific CTL generation as a
correlate of HCV-mediated antileishmanial immunity that is reversed by in vivo CD8 T-cell depletion of
HCV-treated mice. Our findings might be extended to drug-nonresponsive visceral leishmaniasis patients, as
well as against multiple infectious diseases with pathogen-specific immunodominant antigens.
Visceral leishmaniasis (VL), also known as kala-azar, caused
by the intracellular parasite Leishmania donovani, is charac-
terized by defective cell-mediated immunity (32). To date, no
effective vaccines exist against VL, a disease that is fatal if left
untreated and that has resulted in more than 100,000 deaths in
recent epidemics in Sudan and India (26). Since any form of
chemotherapeutic intervention potentially results in the devel-
opment of drug-resistant forms (32, 47, 48), effective antileish-
manial intervention should include immunologically defined
antigen-based therapy targeted effectively to stimulate rel-
evant effector and helper defense mechanisms. Moreover,
failure to appreciate the mechanism and therapeutic targets
governing protective immune response against L. donovani
infection is posing difficulty in devising a suitable vaccine
formulation.
Though not tested against any infectious diseases so far,
hybrid cell vaccine (HCV) has yielded promising results in the
treatment of human cancer. Hybrid cells prepared from the
infusion of tumor and allogeneic dendritic cells induce a tu-
mor-specific CD8 T-cell response resulting in disease regres-
sion or stabilization in melanoma, renal cancer, and breast
cancer patients and causing only minor side effects (classified
as grade I according to World Health Organization toxicity
grading criteria) in a few patients, thus confirming the nontox-
icity of the vaccine (3, 44, 50, 51). Hence, due to the feasibility
of implementation and known ability of hybrid cell vaccination
to generate vigorous major histocompatibility complex (MHC)
class I-restricted CD8 cytotoxic T-lymphocyte (CTL) re-
sponse, we used kinetoplastid membrane protein 11 (KMP-11)
antigen-based HCV therapy in L. donovani-infected mice. Pre-
viously, we have established the efficacy of KMP-11 as an
immunodominant candidate antigen for DNA vaccine against
VL (6). Recently, we have dissected the remarkable antigenic-
ity of KMP-11 by defining 29 MHC class I-restricted epitopes
capable of inducing gamma interferon (IFN-) secretion by
human CD8 T cells (5). In the context of the role of CD8 T
cells in leishmaniasis, a dominant role of vaccine-induced
CD8 T cells been implicated in cutaneous leishmaniasis (CL)
since CD8 T-cell depletion resulted in the abrogation of the
protective efficacy of the LACK-DNA vaccine (14). CD8 T
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cells were also acknowledged to be responsible for the estab-
lishment of resistance in the VL model (34, 43). However, in
the CL model, activated CD8 T cells facilitated IFN- pro-
duction and simultaneously masked the detrimental interleu-
kin-4 (IL-4)-producing Th2 type of immune response (52). In
contrast, our earlier observation suggested that the protective
immune response against L. donovani infection by KMP-11
DNA vaccination associated with a strong antigen-specific
CTL response and high IFN- generation surprisingly did not
suppress an IL-4-producing Th2-type response (6). Due to the
absence of a defined CTL marker in the hamster model, it was
difficult to predict whether the CTL response that failed to
dampen or suppress the Th2 response was restricted to the
CD8 T-cell population (6). Moreover, it has been reported
that, compared to untreated, active VL patients, the frequency
of activated CD8 T cells substantially increased in asymptom-
atic and treated VL patients, along with high IFN-- and IL-
4-producing CD4 T cells (15). Intriguingly, in the same study,
both IFN- production and IL-4 production were found to be
very low in active VL patients, a finding suggestive of a sup-
pressive mechanism acting on both Th1 and Th2 subsets of
T cells in the presence of a low frequency of activated CD8 T
cells. In another clinical study, Leishmania-specific CD8 T
cells have been identified as an important contributor to anti-
leishmanial immunity in asymptomatic VL patients exhibiting
a mixed Th1/Th2 response (25). L. donovani-reactive CD4 T
cells clones secreting both IFN- and IL-4 have also been
isolated from individuals who have recovered from VL after
antimonial treatment (18). Thus far, no mechanism has been
suggested to explain the existence of both IFN--producing
and IL-4-producing CD4 T-cell clones from chemotherapeu-
tically cured or asymptomatic VL patients (15, 18, 25). Hence,
due to the known ability of HCV to activate CD8 T cells, we
reasoned that HCV therapy against L. donovani is likely to
establish a correlation between CD8 T cells and the Th1/Th2
type of immune response. Increasingly, reports are suggesting
that the relevant importance of the Th2 immune response is
clearly Leishmania species dependent since a mixed Th1/Th2
protective response is associated with VL as opposed to the
polarized Th1 protective response observed in CL (17, 18, 21,
27). Although IL-10 is universally acknowledged as a disease-
promoting cytokines in both CL and VL, there are many con-
flicting reports of both IL-4 and IL-13 having opposite roles to
play in VL and being associated with resistance (2, 6, 17, 28, 33,
36, 41, 42). Sacks and coworkers have previously demonstrated
that IL-10 is regulated independently of IL-4 in patients with
active VL and suggested that the source of IL-10 is not clas-
sically defined Th2 cells (16). Since addressing the cellular
basis of coexistence of the mixed Th1/Th2 response in protec-
tive immunity in VL is essential for defining the successful
implementation of a vaccine, our study focused on the HCV-
induced production of the Th1 cytokine IFN- and the Th2
cytokines IL-4, IL-13, and IL-10. Our finding reveals that the
HCV-induced CD8 T-cell-mediated antileishmanial protec-
tive immune response, despite augmenting IFN- production,
specifically suppresses IL-10 but not IL-4 or IL-13 from splenic
T cells, thus accounting for the mixed Th1/Th2 response ob-
served in protection against L. donovani infection.
MATERIALS AND METHODS
Reagents and cell culture. HEPES, penicillin-streptomycin, NaHCO3, 2-mer-
captoethanol, brefeldin A, dimethyl sulfoxide, sodium azide, EDTA, ATP, and
sucrose were purchased from Sigma Aldrich (St. Louis, MO). [3H]thymidine was
obtained from New England Nuclear (Boston, MA). The recombinant mouse
cytokines rmIL-2, rmGM-CSF, rmIL-4, and rmTNF- were purchased from BD
Biosciences (San Diego, CA), and rmMCSF was purchased from Sigma. Cyto-
kine enzyme-linked immunosorbent assay (ELISA) kits for IL-4, IL-10, and
IFN- were obtained from BD Biosciences (San Diego, CA). An IL-13 ELISA
kit was obtained from e-Bioscience (San Diego, CA). The CD4 magnetic
activated cell sorting (MACS) antibody was purchased from Miltenyi Biotec.
RAW 264.7 (H-2d), a murine macrophage cell line, and 2.43, a murine lympho-
blast secreting antibodies to Lyt2.2, were obtained from the American Type
Culture Collection (Rockville, MD). Cells were grown in RPMI 1640 (Invitro-
gen, Grand Island, NY) supplemented with 100 U of penicillin/ml, 100 g of
streptomycin/ml, 4 mM NaHCO3, 20 mM HEPES, and 5  105 M 2-mercap-
toethanol, along with 10% fetal calf serum (Invitrogen), at 37°C in the presence
of a 5% CO2 supply.
Animals, parasites, and infection. BALB/c (H-2d) mice, 4 to 6 weeks old and
reared in our institute facilities, and C57BL/6 (H-2b) mice, 4 to 6 weeks old and
purchased from NIN (Hyderabad, India), were used for experiments with the
prior approval of the animal ethics committee of the Indian Institute of Chemical
Biology (Kolkata, India). L. donovani strain AG83 (MHOM/IN/1983/AG83) was
used for our experiments (6). AG83 was originally obtained from Indian kala-
azar patients and was maintained in golden hamsters as described previously (6).
Promastigotes obtained after transforming amastigotes from infected hamster
spleen were maintained in M199 (Invitrogen) supplemented with antibiotics and
10% fetal calf serum at 22°C. For infection, 4- to 6-week-old BALB/c mice were
injected with 106 promastigotes suspended in saline by the intracardiac route
using a 28-gauge needle.
Generation of BM-M and BM-DC and transfection. Bone marrow-derived
dendritic cells (BM-DC) were generated from bone marrow progenitors in the
presence of rmGM-CSF and rmIL-4 (1). A total of 106 nonadherent bone
marrow cells/ml, collected after passage of marrow from the tibias and femurs of
BALB/c (H-2d) or C57BL/6 (H-2b) mice, were seeded in a 24-well plate in the
presence of rmGM-CSF (150 U/ml) and rmIL-4 (75 U/ml) and then cultured for
3 days in a 37°C incubator with a 5% CO2 supply. On day 3, nonadherent cells
(2.5  106/2 ml/well) were again transferred and supplemented with complete
medium and cytokines, and subsequently cultures were fed with rmGM-CSF and
rmIL-4 on days 5 and 7. After 10 days, the nonadherent cells were collected.
During the last 14 to 18 h of BM-DC culture, the cells were grown in the
presence of rmTNF- (20 ng/ml), providing DC maturation stimulus. Bone
marrow-derived macrophages (BM-M) were obtained similarly from bone mar-
row cells of BALB/c (H-2d) mice in the presence of 0.2 ng of rmGM-CSF/ml and
50 ng of rmM-CSF/ml, followed by incubation at 37°C with a 5% CO2 supply for
24 h. Nonadherent cells were transferred to a new well with the same medium
and cytokines and then cultured for an additional 5 to 7 days at 37°C in a CO2
incubator (23).
Endotoxin-free plasmids were isolated by using an EndoFree Plasmid Mega
kit (QIAGEN, GmbH, Hilden, Germany) according to the manufacturer’s in-
structions and used for the transfection of BM-DC and BM-M with Effectene
reagent (QIAGEN) according to the manufacturer’s protocols. The transfection
efficiency of BM-M and BM-DC was estimated by counting red fluorescent cells
under an inverted fluorescence microscope and by flow cytometry after trans-
fection with a red fluorescent protein carrying plasmid pDsRED (BD Clontech).
BM-DC showed a transfection efficiency of 6%, while BM-M showed a
transfection efficiency of 	18% (9).
Electrofusion parameters for hybrid cell generation and determination of
fusion efficiency. Electrofusion of allogeneic BM-DC with KMP-11 DNA-trans-
fected syngeneic BM-M and syngeneic BM-DC was performed as described
previously (37) with several modifications. Briefly, partnering cells were washed
thoroughly with sterile 0.3 M isotonic sucrose solution. Immediately before
fusion, 2  107 of viable untransfected allogeneic BM-DC/ml and 2  107/ml of
viable syngeneic BM-M or BM-DC transfected with KMP-11 DNA/ml were
mixed at a ratio of 1:1 to yield a density of 2  107/ml in an inert wax-coated
electroplated cuvette (Bio-Rad, Hercules, CA). After a series of standardization
events for electrofusion, partnering cells were subjected to a range of alignment
voltage (10 to 40 direct current V) and pulse voltage (100 to 400 V) (see Fig. S1
in the supplemental material). For therapeutic vaccination purposes, hybrids of
KMP-11-transfected BM-M and BM-DC were used for their high percentage of
fusion (	30%), which corresponded to a high viability (	90%) and greater
transfection efficiency of macrophages. Maximum fusion and viability were ob-
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served at an alignment voltage of 20 V (50 V/cm) with simultaneous application
of 625 V/cm of square wave pulse (see Fig. S1 in the supplemental material).
Fusion of KMP-11-transfected BM-DC with allogeneic BM-DC was not consid-
ered for HCV since DC-DC hybrid formation never exceeded 15.5%, with a
corresponding low viability (43%) at the tested ranges of alignment and pulse
voltage. For analysis of a true fusion event, hybrid cells were analyzed by flow
cytometry and further verified by fluorescence microscopy. Briefly, prior to
electrofusion allogeneic BM-DC were labeled with intracellular dye CFSE (Mo-
lecular Probes, Inc., Eugene, OR), and syngeneic BM-M after KMP-11 trans-
fection were stained with the membrane dye PKH26 (Sigma) according to the
manufacturer’s instructions and subsequently subjected to electrofusion proce-
dure. The fusion efficiencies were 	30% as evident from double-stained cells
detected by flow cytometry (Becton Dickinson, San Jose, CA) and as further
verified by fluorescence microscopy (Leica Microsystems, GmbH, Wetzlar, Ger-
many) when superimposed (see Fig. S1 in the supplemental material). Expres-
sion of CD11b and CD11c was also determined to ascertain the purity of BM-M
and BM-DC by flow cytometry, along with the expression of MHC class I, MHC
class II, CD80, and CD86 of the partnering cells that showed high expression of
all of these cell surface molecules (data not shown). Hence, for HCV prepara-
tion, partnering cells suspended in isotonic sucrose solution were first dielectro-
phoretically aligned to establish close cell-cell contact by applying a low voltage
(20 V direct current for 20 s) in a spatially nonuniform electric field in an
electrofusion chamber, followed by a simultaneously applied single square pulse
of 625 V/cm (Gene Pulser Xcell; Bio-Rad) (55). After electrofusion, the cuvette
was left undisturbed for 5 min before the cells were suspended in relaxation
buffer (100 mM KCl, 3 mM NaCl, 1.25 mM EDTA, 10 mM HEPES, 0.5 mM
ATP) for 15 min for complete membrane overlap. Cell viability, determined each
time after electrofusion by dye exclusion, was usually 	90%.
Therapeutic vaccination and in vivo CD8 T-cell depletion protocol. For
vaccination, BALB/c mice infected with L. donovani for 2 months were divided
into several groups receiving one to six intravenous (i.v.) injections of 5  105
cells/animal/100 l of phosphate-buffered saline given 5 days apart. The follow-
ing types of cells were used for therapeutic vaccination purposes: (i) syngeneic
BM-DC transfected with KMP-11 DNA (syngeneic BM-DC–KMP-11); (ii) syn-
geneic BM-M transfected with KMP-11 DNA (syngeneic BM-M–KMP-11):
(iii) untransfected syngeneic BM-DC (syngeneic BM-DC); (iv) untransfected
syngeneic BM-M (syngeneic BM-M); (v) hybrids of KMP-11 DNA-trans-
fected syngeneic BM-M and allogeneic BM-DC (HCV); and (vi) hybrids of
untransfected syngeneic BM-M and allogeneic BM-DC (syngeneic BM-
Mallogeneic BM-DC). Therapeutic vaccination with blank vector (pCMV-
LIC)-transfected syngeneic BM-DC/BM-M and hybrids of blank vector-trans-
fected syngeneic BM-M and allogeneic BM-DC was also performed. For a dose
kinetics study of mixed (unfused) cells and pulsed, electrofused (hybrid cells)
cells, mice were sacrificed after 15 days of receiving last injection(s) (one to six
doses) of mixed unfused cells or hybrid cells (HCV). For organ parasite burden
detection and all other experiments, mice were sacrificed 15 days after receiving
six doses of HCV or six injection doses of different cell types as described above.
For CD8 T-cell depletion, groups of mice therapeutically vaccinated with HCV
were treated intraperitoneally with 1 mg of anti-CD8 (2.43) antibody 24 h before
every HCV therapy.
Determination of splenic and hepatic parasite burden by serial dilution
method. The parasite burden was quantified in spleen and liver tissue by serial
dilution assay as described previously (6). Wells were examined for viable and
motile promastigotes every 3 days, and the reciprocal of the highest dilution that
was positive for parasites was considered to be the parasite concentration per
milligram of tissue.
Parasite soluble antigen preparation and rKMP-11 protein purification. The
soluble leishmanial antigen (SLA) used in the T-cell proliferation assay and the
CTL assay was prepared from stationary-phase promastigotes of L. donovani
(AG83) according to a published protocol (6). rKMP-11 protein under native
conditions was purified by Ni-nitrilotriacetic acid affinity column from pQE-30
plasmid (kindly provided by H. Moll, University of Wurzburg, Wurzburg, Ger-
many) containing KMP-11 open reading frame aligned in frame with the His tag
as described previously (6).
T-cell proliferation and CTL assay. A T-cell proliferation assay was performed
as described previously (6). Briefly, a single cell suspension (105 cells/well) of
splenocytes from different experimental groups of mice as described above was
plated in triplicate in 96-well plates and allowed to proliferate for 3 days at 37°C
in a 5% CO2 incubator in the presence of different SLA concentrations (0.5, 5,
or 50 g/ml). Eighteen hours before they were harvested, the cells were pulsed
with 1 Ci (6.7 Ci/mmol) of [3H]thymidine/well. [3H]thymidine uptake, as an
index of proliferation, was measured by a liquid scintillation counter (TRI CARB
2100TR; Packard).
For the CTL assay, nonadherent splenocytes from HCV-treated mice (with or
without depletion of CD8 T cells) and other different experimental groups of
mice, as mentioned above, were expanded with SLA for 7 days. Recombinant
IL-2 (20 U/ml) was added 3 days later (41). After this, effector T cells were
incubated with 51Cr-labeled targets (RAW 264.7 cells transfected either with
pCMV-LIC, pCMV-LIC KMP-11, or pEGFP-N1) in round-bottom 96-well
plates (200 l) at different effector/target (E:T) ratios (6:1, 12.5:1, 25:1, or 50:1)
for 4 h. Target cells (106) were labeled with 100 Ci of Na2CrO4 (2.5 mCi/38.4
g/ml; BARC, Mumbai, India) as described previously (6). After 4 h of incuba-
tion,100 l of culture supernatant after centrifugation was collected and counted
in triplicates in a liquid scintillation counter (TRI CARB 2100TR; Packard).
Specific lysis was calculated according to the following formula: % specific
lysis 
 [(sample  spontaneous release)/(maximum release  spontaneous
release)]  100.
RNA isolation and quantitative transcript analysis of IFN-, IL-4, IL-13, and
IL-10 from splenic CD4 T lymphocytes stimulated with rKMP-11. Splenic
lymphocytes (5  106/ml) were stimulated with rKMP-11 protein (5 g/ml) for
18 h. Total RNA from MACS-purified CD4 T cells from L. donovani-infected
and HCV-treated (with or without depletion of CD8 T cells) BALB/c mice
were isolated according to the RNeasy minikit isolation procedure (QIAGEN)
and was individually analyzed (eight animals/group) by real-time reverse tran-
scription-PCR. Briefly, 2-g samples of RNA from different experimental groups
of mice were first utilized for cDNA synthesis by random hexamers (Invitrogen)
using Superscript II (Invitrogen) and PCR was performed as described previ-
ously (12). Briefly, a common master mix (SYBR green JumpStart Taq Ready-
Mix; Sigma), gene-specific primers, and cDNA were used for amplification in an
iCycler PCR detector (Bio-Rad) according to the manufacturer’s instructions.
The cycling conditions for all of the genes of interest were 12 min at 95°C,
followed by 40 cycles of denaturation at 95°C for 15 s, annealing at a gene-
specific temperature for 30 s, and extension at 72°C for 45 s. The expression of
a target gene was quantified by using the formula 2CT, where CT 

[CT(target)  CT(-actin)]treated  [CT(target)  CT(-actin)]control. Each gene was
normalized to the housekeeping gene (-actin) before the fold change was
calculated to account for variations between different samples. After each real-
time reaction, a melting curve was generated to ensure that only gene-specific
PCR product was generated.
The following primers were used to amplify the following genes as described
by Grogan et al. (12) except -actin primers: IL-10, sense (5-GGTTGCCAAG
CCTTATCGGA-3); IL-10, antisense (5- ACCTGCTCCACTGCCTTGCT-3);
IL-4, sense (5-AGATCATCGGCATTTTGAACG-3); IL-4, antisense (5-TTT
GGCACATCCATCTCCG-3); IFN-, sense (5-GGATGCATTCATGAGTAT
TGC-3); IFN-, antisense (5-CCTTTTCCGCTTCCTGAGG-3); IL-13, sense
(5-GCTTATTGAGGAGCTGAGCAACA-3); IL-13, antisense (5-GGCCAG
GTCCACACTCCATA-3); -actin, sense (5-AGAGGGAAATCGTGCGTGA
C-3); and -actin, antisense (5-CAATAGTGATGACCTGGCCGT-3).
Analysis of quantitative expression of the T-cell differentiation transcription
factors T-bet and GATA-3. To study the expression of T-bet and GATA-3,
splenocytes (5  106/ml) from different groups of infected and HCV-treated
mice were stimulated with 4  106 live promastigotes/ml for 6 days (20). After-
ward, CD4 T cells from promastigote-stimulated splenocytes, after Ficoll gra-
dient, were purified by MACS and used for RNA isolation. cDNA was synthe-
sized from 2 g of RNA according to the above-described conditions, and
quantitative PCR was performed under the following cycling conditions: 95°C for
12 min, followed by 40 cycles of 95°C for 30 s, 60°C for 60 s, and 72°C for 45 s.
The following primers were used to amplify the indicated genes as described by
Grogan et al. (12): GATA-3, sense (5-AGAACCGGCCCCTTATCAA-3);
GATA-3, antisense (5-AGTTCGCGCAGGATGTCC-3); T-bet, sense (5-CA
ACAACCCCTTTGCCAAAG-3); and T-bet, antisense (5-TCCCCCAAGCA
GTTGACAGT-3).
Measurement of IFN-, IL-4, IL-13, and IL-10 protein levels in rKMP-11
stimulated macrophage-depleted splenic lymphocyte culture supernatant. Single
cell suspensions (5  106/ml) of pooled splenocytes (four mice/group), depleted
of macrophages by the application of two successive 90-min plastic plate adher-
ence procedures as described previously (11), from different experimental groups
of mice were stimulated with 5 g of rKMP-11 protein/ml for 72 h in a 37°C
incubator with a 5% CO2 supply. All of the supernatants were collected and
frozen at 70°C for subsequent analysis. IFN-, IL-4, IL-10, and IL-13 were
evaluated from culture supernatants by cytokine ELISAs according to the man-
ufacturer’s protocol. The detection limits for the cytokines were as follows:
IFN-, 31.3 pg/ml; IL-4, 7.8 pg/ml; IL-13, 30 pg/ml; and IL-10, 31.3 pg/ml.
Statistical analysis. A paired two-tailed Student t test was used for statistical
analysis of the data. P values of 0.05 were considered statistically significant.
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The results are represented as means  the standard error (SE) as indicated in
the figure legends.
RESULTS
Therapeutic vaccination with HCV clears both the splenic
and the hepatic parasite burden that is completely abrogated
by in vivo CD8 T-cell depletion. The virulent L. donovani
strain AG83 (MHOM/IN/1983/AG83) used in the present
study kinetics of infection different from that of the Sudanese
(LV9 and LV82) and Ethiopian strains of L. donovani used in
other studies (28, 40). After AG83 challenge, an exponential
rise in both the splenic and the hepatic parasite burdens occurs
until 5 months postinfection in a BALB/c mice model (29, 4).
Since a cure from late-stage infection, at which the reversal of
immune dysregulation is most critical, is the most desirable
indicator of immunotherapeutic efficacy, we tried HCV ther-
apy in a BALB/c mouse model at 60 days postinfection. We
initially studied the detailed dose kinetics of mixed (unpulsed)
and hybrid cells and its efficacy in parasite reduction from both
the of the affected organs: spleen and liver (Fig. 1A and B).
Considering the percentage of hybrid cell formation (	30%)
and transfection efficiency of BM-M (	18%), a single dose of
FIG. 1. HCV therapy in L. donovani-infected mice confers sterile protection that is completely abrogated by CD8 T-cell depletion. For
vaccination, L. donovani-infected BALB/c mice were treated 60 days postinfection with i.v. injections of any one type of the cells mentioned in
Materials and Methods. Therapeutically treated mice were sacrificed 15 days after the last injection. The data represent the means  the SE for
24 animals per group. Figures in parentheses above the bars indicate percentages of mice showing complete absence of parasites in the spleen or
liver as determined by serial dilution assay. (A and B) Comparative dose-response results for mixed cells and electrofused cells (HCV) in L.
donovani (AG83)-infected BALB/c mice (2 months postinfection) receiving one to six i.v. injections of unpulsed (mixed) cells or pulsed (hybrid
cells) in terms of reduction of parasite burden (bar diagram) and sterile cure (data in parentheses) in the spleen (A) and liver (B). In infected
animals, the splenic parasite burden ranged from 4  107  0.42  107 (at the time of assessing the result of one HCV dose) to 15.4 
107  0.34  107 (at the time of assessing the result of six doses of HCV). Similarly, the hepatic parasite burden in infected mice ranged
from 7.6  107  1.06  107 (at the time of assessing the result of one HCV dose) to 27.7  107  1.46  107 (at the time of assessing
the result of 6 doses of HCV). (C and D) Organ parasite burden of infected BALB/c mice receiving six i.v. injections of either HCV (with or
without depletion of CD8 T cells) or other indicated cell types at 5-day interval. At 24 h before each HCV therapy, the mice were treated with
1 mg of anti-CD8 (2.43) antibody for successful depletion of CD8 T cells. Splenic (C) and hepatic (D) parasite burdens of infected BALB/c mice
therapeutically treated with the above-mentioned cell types. The percentages of mice showing sterile cure are indicated in parentheses above the
bars of the respective groups.
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HCV effectively introduced 	3  104 KMP-11-transfected
fused cells. The dose response of HCV showed its remarkable
therapeutic potential since a 	80% reduction of splenic and
hepatic parasite load was observed in animals treated with a
single dose of HCV. More significantly, two doses of HCV
resulted in completely undetectable amastigotes in 3 of 24 and
6 of 24 mice in the spleen and the liver, respectively. Compar-
ative evaluation of therapeutic vaccination efficacy achieved by
mixed, unpulsed cells (KMP-11-transfected syngeneic BM-M
mixed with allogeneic BM-DC) showed a maximum of 25%
reduction in organ parasite burden after two doses, reaching a
maximum reduction of 45% at six vaccination doses (Fig. 1A
and B). This result established hybrid cell formation as an
essential requirement for vaccine efficacy, whereas at a maxi-
mum of six doses of HCV the spleens of 	66% of mice (16 of
24 mice) treated with HCV showed a complete absence of
promastigotes in the serially diluted culture. The remaining
33.33% of HCV-treated mice (8 of 24 mice) showed a 	98%
reduction in splenic parasite burden, as determined by serial
dilution assay (Fig. 1C). At a similar dose, complete clearance
of hepatic parasite burden was observed in 87.5% of the hybrid
cell vaccinated mice (21 of 24 mice), while the remaining an-
imals (3 of 24 mice) showed 99% reduction in the liver
parasite burden, as determined by standard serial dilution as-
say (Fig. 1D). Although less sensitive than the serial dilution
assay, the gold standard for detecting amastigotes for deter-
mining a clinical cure, microscopic evaluation of the parasite
burden in Giemsa-stained smears was also attempted in our
study (45, 46, 53). If no parasites are identified by this proce-
dure in the splenic aspirate, the patients are said to be “cured”
(45). Remarkably, no amastigotes could be detected by light
microscopy (data not shown) in impressions of Giemsa-stained
tissue stamp smears of transverse sections of spleens and livers
from all of the HCV-treated mice that could be described as
the classical definition of a “cure.” To evaluate the contribu-
tion of an allo-MHC response with a syngeneic MHC response,
the therapeutic efficacy of HCV was compared to KMP-11
DNA-transfected syngeneic antigen-presenting cells (APC).
Hence, KMP-11-transfected syngeneic BM-DC or KMP-11-
transfected syngeneic BM-M were also injected six times i.v.
every 5 days. Comparative doses of KMP-11-transfected syn-
geneic BM-DC–BM-M could only confer  64% and 70%
clearance of the splenic parasite burden (P  0.0005) and
67% and 74% reduction of the hepatic parasite burden
(P  0.0005), respectively (Fig. 1C and D). Unlike HCV-
treated mice, a sterile cure was not observed in any of trans-
fected APC-treated mice. Neither the control groups of un-
transfected syngeneic BM-M or BM-DC (P  0.5) nor the
hybrids of untransfected syngeneic BM-M and allogeneic-
BM-DC (P 	 0.05) could induce any significant protection in
organ parasite burden. Expectedly, therapeutic vaccination
with blank vector-transfected syngeneic BM-DC, blank vector-
transfected syngeneic BM-M, and blank vector-transfected
fused cells could not confer any protection (data not shown).
Since the main objective of HCV therapy relies on its po-
tential to generate a vigorous CD8 CTL response, we tried to
assess the role of CD8 T cells in HCV immunotherapy by
depleting CD8 T cells. In these experiments, depletion of
CD8 T cells was preferred at the time of vaccination rather
than at the time of infection to limit the induction of HCV-
mediated antigen-specific CD8 T cells but not to limit the
endogenous repertoire of CD8 T cells during the natural
course of infection. It was observed that CD8 T-cell depletion
completely abrogated HCV efficacy where the CD8 T-cell-
depleted mice showed a high amastigote burden (13.2  107 
1.88  107 in the spleen and 22.5  107  1.95  107 in
the liver). Similar to the observation of Gurunathan et al. (14),
we observed that the administration of anti-CD8 (2.43) did not
alter the frequency and function (in terms of IL-12 production)
of the CD11c CD8 DC population (data not shown), known
to be involved in CTL priming (7), whereas 	98% of the
CD3 CD8 T cells were successfully depleted. Thus, it was
conclusively established that CD8 T cells play a cardinal role
in the HCV-mediated curative response.
HCV induces a strong anti-KMP-11 CD8 CTL response in
L. donovani-infected BALB/c mice that is abolished by CD8
depletion. Abrogation of protective efficacy of LACK-DNA in
the murine CL model due to CD8 T-cell depletion is sugges-
tive of vaccination-induced dominant role of the CD8 T-cell-
mediated protective immune response, although the role of
CD8 restricted CTLs has not been exclusively implicated in
these studies (14). Thus, we proceeded to measure KMP-11-
specific CTL generation in therapeutically cured HCV-treated
mice. Splenocytes stimulated for 7 days with SLA from HCV-
treated mice showed a 58% lysis of 51Cr-labeled KMP-11-
transfected syngeneic M (RAW 264.7) at the highest E:T
ratio (50:1; P  0.0005). KMP-11-transfected BM-DC or
KMP-11-transfected BM-M treated mice showed maximal
lysis values of 29 and 31%, respectively, at an E:T ratio of 50:1
(P  0.005) (Fig. 2). The infected and other control groups of
mice showed 9% lysis of radiolabeled targets at a 50:1 E:T
ratio and did not differ significantly between the infected group
and hybrids of the untransfected syngeneic BM-M and allo-
geneic BM-DC treated control groups, a finding suggestive of
a severely impaired CD8 CTL response due to L. donovani
infection in the BALB/c model. Specificity of lysis was further
corroborated by the failure of the nonadherent splenic effector
T cells to lyse syngeneic M transfected with either enhanced
green fluorescent protein expressing pEGFP-N1 construct or
transfected with blank vector pCMV-LIC (data not shown).
The role of allogeneic MHC in generating a strong CTL re-
sponse was also supported by the observation that mice treated
with HCV showed a statistically significant level of CTL gen-
eration (18% lysis) even at the lowest E:T ratio (6:1; P 0.05),
whereas KMP-11-transfected syngeneic BM-M or BM-DC
treated mice failed to show significant lysis at the lowest E:T
ratio. The CTL response was completely impeded in CD8
T-cell-depleted mice, resulting in the failure of lysis of KMP-
11-transfected targets, confirming an essential role of CD8
CTL in the HCV-mediated curative response.
SLA-induced T-cell proliferation in HCV-treated mice is
impaired by CD8 depletion. The cell-mediated immune re-
sponse is impaired in VL patients, as well as in experimental
models, and is marked by T-cell anergy specific to Leishmania
antigens (6). Since hybrid cell vaccination could reverse im-
paired cell-mediated immune response by inducing strong
CTL generation, we were interested in determining the effect
of HCV therapy in an SLA-specific T-cell proliferative re-
sponse. All of the partially protected and HCV-treated mice
showed	4-fold enhancement (P 0.0005) of the proliferative
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response versus the infected control at an SLA stimulation of
5 g/ml, and HCV-treated mice showed a 2-fold greater
proliferation index (P  0.05) compared to KMP-11-trans-
fected syngeneic BM-M or KMP-11-transfected syngeneic
BM-DC treated mice at a 5-g/ml SLA stimulation (Fig. 3).
CD8 T-cell-depleted HCV-treated mice showed similarly im-
paired T-cell proliferation compared to infected controls (P 
0.5).
Only IL-10, and not IL-4 or IL-13, is considerably down-
regulated in HCV-treated mice at both mRNA and protein
levels, which is reversed after CD8 T-cell depletion. In clin-
ical scenarios, an increase in both IFN-- and IL-4-producing
CD4 T cells has been observed in VL patients that have
recently recovered (15). Moreover, CD4 T cells isolated from
asymptomatic and chemotherapeutically cured VL individuals
exhibited both Th1 and Th2 cytokine profiles, such as IFN-
and IL-4, respectively (25). Thus, we initially proceeded to
measure the transcriptional expression of the Th1 signature
cytokine IFN- and the Th2 cytokines IL-4, IL-13, and IL-10
from rKMP-11-stimulated MACS-purified splenic CD4 T
cells of HCV-treated (with or without depletion of CD8 T
cells) and infected mice by real-time PCR (Fig. 4A). After
HCV-therapy, IFN- transcripts in CD4 T cells were found to
be expressed 3.65-fold more compared to infected controls
(Fig.4Aa). Among Th2 cytokines, IL-4 mRNA was enhanced
8.8-fold, whereas IL-13 was enhanced 4.43-fold in HCV-
treated mice compared to infected controls (Fig. 4Ac and d).
On the other hand, IL-10 mRNA was downregulated by 24.68-
fold after HCV therapy (Fig.4Ab). Due to CD8 T-cell deple-
tion, IFN- was downregulated by 2.44-fold, IL-4 was down-
regulated by 5.51-fold, and IL-13 was downregulated by
3.54-fold with respect to the infected control. Surprisingly,
IL-10 mRNA in splenic CD4 T cells was significantly upregu-
lated by 2.12-fold versus the infected control due to CD8
T-cell depletion (P  0.005). In fact, the IL-10 transcript was
increased by 	50-fold by CD8 depletion of HCV-treated mice
compared to treated mice with an intact CD8 T-cell compart-
ment. The results suggest that IL-10 mRNA is the only Th2
cytokine that was strongly downregulated, while other two Th2
cytokines—IL-4 and IL-13—were moderately upregulated,
along with IFN-, after HCV therapy. Thus, the effect of de-
pletion on IFN-, IL-4, and IL-13 from CD4 T cells was
FIG. 2. HCV elicits a vigorous anti-KMP-11-specific CTL response in L. donovani-infected mice that is completely abrogated by CD8 T-cell
depletion. CTL generation was assayed by a standard 51Cr release assay in mice receiving six doses of HCV (with or without depletion of CD8
T cells) with the other indicated groups. Spontaneous release was 5%. The results are representative of five individual experiments (five
animals/group/experiment), and the data represent the mean  the SE. At both 50:1 and 6:1 E:T ratios, hybrid cell-vaccinated mice showed
significant lysis (*, P  0.0005; and **, P  0.0001, respectively) with respect to infected controls, while syngeneic KMP-11-transfected
APC-vaccinated mice showed statistically significant lysis of targets only at 50:1 (o, P 0.005) compared to infected controls. Anti-CD8 Abs treated
hybrid cell vaccinated mice were unable to generate any effective CTL response as reflected in the figure.
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similar since all were significantly downregulated (P  0.05).
These observations suggest that activated CD8 T cells in-
duced by HCV therapy override the suppressive effect of IL-10
by elevating both Th1 cytokine IFN- and Th2 cytokines IL-4
and IL-13.
Based on these observations, we reasoned that the suppres-
sive effect of IL-10 might act on both Th1 and Th2 differenti-
ation of CD4 T cells, thereby impeding activation of both
effector T helper subsets. Hence, we wanted to study the
mRNA expression profiles of the CD4 Th1 and Th2 cell-
lineage-specific transcription factors T-bet and GATA-3, re-
spectively. In CD4 T cells, T-bet is rapidly and specifically
induced in developing Th1 cells only and is a feasible candidate
for involvement in the Th1-specific expression of the IFN-
gene (49). On the other hand, reduction in GATA-3 expres-
sion in differentiated Th2 cells resulted in decreased produc-
tion of IL-4 and IL-13 (54). High levels of GATA-3 instruct
effector T cells to produce IL-4 and IL-13 by inducing charac-
teristic DNase hypersensitivity sites in the IL-4 locus and IL-13
promoters (19, 22). Furthermore, GATA-3 is not known to
influence IL-10 gene expression (39). Not only are T-bet and
GATA-3 necessary for the development of CD4 Th1 and Th2
effector phenotypes, respectively, these lineage-specific tran-
scription factors are prime candidates for the maintenance of
cytokine memory from committed CD4 T helper cells (24).
To simulate the in vivo condition of splenic CD4 T-cell in
infected and treated mice, splenic T cells were stimulated with
L. donovani promastigotes for 6 days, and RNA was isolated
from MACS-purified CD4 T cells to study the expression
profiles of GATA-3 and T-bet transcripts by real-time PCR.
The extent of T-bet induction was found to be increased 5-
fold (Fig.4Ba), whereas an 6-fold increase in GATA-3 tran-
scription factor (Fig.4Bb) suggested the clonal expansion of
both Th1 and Th2 subsets due to curative HCV therapy in
consonance with substantial upregulation in IFN-, as well as
IL-4 and IL-13, transcripts from splenic CD4 T cells. Our
results also indicated that the observed surge in IFN-, IL-4,
and IL-13 are indeed from Leishmania-reactive CD4 Th1 and
Th2 clones generated in vivo and not due to artifactual in vitro
skewing of CD4 T lymphocytes by rKMP stimulation.
Cytokines measurement at protein level in macrophage-de-
pleted splenocytes reflected a similar representation with a
	6-fold (P  0.001) surge in IFN- production after HCV
immunotherapy (Fig.4Ca), while Th2 cytokines IL-4 and IL-13
(Fig. 4Cc and d) were elevated by 4.2- and 2.74-fold, respec-
tively. IL-10 showed 	5.5-fold reduction in cured mice after
HCV therapy (Fig.4Cb). CD8 depletion resulted in reduced
expression of IFN- (2.19-fold), as well as IL-4 (1.88-fold) and
FIG. 3. HCV-treated mice restore T-cell anergy to SLA that is significantly impaired by CD8 depletion. The results are representative of three
individual experiments (five animals/group), and the data represent the means of triplicate wells  the SE. Proliferation was measured by
determining the [3H]thymidine incorporation. At a 5-g/ml SLA stimulation, the double asterisks represent P  0.0001 for HCV and the single
asterisk represents P 
 0.1219 for HCV-treated CD8 T-cell-depleted mice with respect to the infected group.
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IL-13 (1.48-fold), compared to infected mice. In accordance
with transcriptional analysis, IL-10 protein level showed 2.65-
fold elevated expression in CD8-depleted HCV-treated mice
(P  0.0001) with respect to infected controls. Compared to
HCV-treated animals, CD8 depletion resulted in a 	15-fold
increase in IL-10 expression (Fig.4Cb). Although we did not
compare IL-4, IL-13, and IL-10 mRNA expressions from pu-
rified CD8 T cells of splenic lymphocytes of HCV-treated
mice with infected controls (the CT values of these Th2 cyto-
kine genes from CD8 T cells were consistently found to be
	35 in both the groups), it is unlikely that the surge of IL-4 and
IL-13 in HCV-treated mice is contributed by CD8 T cells.
Nevertheless, it may be argued that the CD8 T-cell popula-
tion present in macrophage-depleted splenocytes prepared for
ELISA contributed to a 	6-fold increased IFN- production
after HCV therapy. These results along with cytokine tran-
script data suggested that IFN-, IL-4, and IL-13 protein levels
were elevated from the Leishmania-reactive Th1 and Th2
clones in splenic lymphocytes of HCV-treated mice, whereas
the IL-10 level was highly suppressed after immunotherapy. In
the absence of activated CD8 T cells induced by HCV ther-
apy, a suppressive effect of IL-10 is exerted on both Th1 and
Th2 cytokines. Overall, the results suggest that the IL-10-rich
splenic environment known to be created in the effector phase
FIG. 4. (A) HCV therapy downregulates the IL-10 transcript from splenic CD4 T cells but not IL-4 and IL-13. Real-time PCR analysis was
performed to detect the fold change in mRNA expression profiles of IFN- (a), along with the Th2 cytokines IL-10 (b), IL-4 (c), and IL-13 (d),
in MACS-purified CD4 splenic lymphocytes (5  106/ml) of infected, HCV-treated mice (with or without depletion of CD8 T cells) versus
normal BALB/c mice in response to 18 h of stimulation with rKMP-11 protein (5 g/ml). The results are representative of eight individual mice
per group analyzed separately, and the data represent the means  the SE. The expression of a target gene was quantified by using the formula
described in Materials and Methods. (B) HCV therapy significantly upregulates GATA-3 along with T-bet. The results of an analysis of the fold
change in mRNA expression of the Th1 polarizing transcription factor T-bet (a) and the Th2 polarizing transcription factor GATA-3 (b) in splenic
CD4 T lymphocytes of infected, HCV-treated mice versus normal BALB/c mice are shown. The results are representative of eight individual mice
per group analyzed separately, and data represent the means  the SE. (C) Only the IL-10 protein level is significantly reduced but Th1 cytokine
IFN- and Th2 cytokines IL-4 and IL-13 are elevated after HCV therapy. ELISA measurements of the protein levels of IFN- (a), IL-10 (b), IL-4
(c), and IL-13 (d) were done with the supernatants of splenic lymphocytes (5  106/ml) depleted of macrophages from mice receiving therapeutic
HCV treatment (with or without depletion of CD8 T cells) and from infected mice (four animals/group) stimulated with rKMP-11 protein (5
g/ml). The results are representative of three experiments, and the data represent the means  the SE.
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of L. donovani infection is significantly downmodulated by
HCV therapy.
DISCUSSION
Our study convincingly shows that hybrid cell immunother-
apy, until now not implemented in the infectious disease
model, cures L. donovani-infected BALB/c mice contingent on
the generation of an antigen-specific CD8 CTL response.
While cancer immunotherapy with HCV uses 3 to 25 doses of
HCV to clinically stabilize patients with metastatic melanoma
and breast and renal carcinoma (3, 50, 51), a single dose of
HCV is sufficient to eliminate 	80% of the parasites in late-
stage L. donovani infection. In the context of the steady
emergence of drug-resistant strains to all chemotherapeutic
interventions, including the recently approved oral drug Milte-
fosine, the broad potential of HCV as a defined immunother-
apeutic intervention cannot be ignored in future VL clinical
trials. While CD8 T cells have gained importance in govern-
ing protective immunity in VL (34, 43), their association with
Th2 cytokines has been related to the suppression of detrimen-
tal Th2 response in CL model (52). In our study, a decrease in
or complete eradication of the parasite burden directly was
correlated with HCV-induced generation of a strong antigen-
specific CD8 CTL response. In a departure from the notion
of the suppression of detrimental Th2 response by activated
CD8 T cells observed in experimental CL, the Th2 cytokines
IL-4 and IL-13 were not found to be suppressed by the elici-
tation of a vigorous anti-KMP-11-specific CD8 T-cell re-
sponse and high IFN- production due to HCV therapy. Our
finding is in agreement with clinical findings wherein both
IFN- and IL-4 CD4 T cells have been isolated from
asymptomatic and cured VL patients (15, 25), as well as in
agreement with experimental findings wherein an increased
frequency of IFN-- and IL-4-producing splenic and hepatic
cells was associated with a decreased L. donovani burden as a
result of curative anti-CTLA monoclonal antibody therapy
(31). Our observations also strongly indicated that IL-10 was
the only Th2 cytokine suppressed by activated CD8 T cells
after HCV therapy. Our findings also support a previous report
on patients with active VL, in which the transcript level of
IL-10 was significantly elevated but eventually decreased mark-
edly with the resolution of the disease (16). The role of the Tc2
population of CD8 T cells as potential sources of IL-4, IL-13,
and IL-10 was ruled out since the purified CD8 T cells of
HCV-treated mice did not show detectable transcripts of these
three cytokines (CT [threshold cycle] 	 35) (data not shown).
Curiously, the production of IFN-, as well as the production
of IL-4 and IL-13, was significantly diminished by CD8 T-cell
depletion in HCV-treated mice, whereas IL-10 production was
greatly enhanced. Hence, the strong association of a curative
response found with the suppression of IL-10, and not other
Th2 cytokines, with HCV-mediated therapy points to the spe-
cific inhibition of IL-10 by activated CD8 T cells. It therefore
might also be reasonable to argue that the suppression of Th2
cytokines by CD8 T cells might principally involve the sup-
pressive activity of IL-10-producing T-cell subsets. Besides be-
ing a potent suppressor of all known microbicidal effector
functions of macrophages, IL-10 can also negatively regulate
both Th1 and Th2 response to antigen (13). Studies in mice
(30) and humans (16) indicate that IL-10 is the major immu-
nosuppressive cytokine in VL. Moreover, it has been pointed
out that in human VL, IL-10 is not produced from classical
Th2 cells (16). Thus, in L. donovani infection IL-10 is increas-
ingly being designated as the suppressive cytokine produced
from a population of regulatory T cells (8); expansion and/or
activation of these cells might be able to suppress both Th1 and
Th2 cells. Reportedly, in L. donovani infection, an IL-10-rich
splenic environment is created during the effector phase of the
antileishmanial immune response by IL-10-secreting CD25
suppressor T cells that inhibit the activation of naive T cells
(8). Interestingly, it has been recently shown that IFN- pro-
duced by tumor-specific CD8 CTL cells inhibits the genera-
tion and/or activation of suppressive regulatory T cells (35).
Hence, it is worth speculating that vaccine-induced activated
CD8 T cells are able to downregulate IL-10 that, in turn,
resulted in the release of both Th1 and Th2 cells to produce
IFN- from the former cell population and IL-4 and IL-13
from the latter cell population. Alternatively, it also remains a
distinct possibility that HCV therapy may also expand preex-
isting, antigen-specific CD8 T cells by directly or indirectly
releasing them from suppressive control by T regulatory (Treg)
cells. In the present study, the T-cell anergy in response to SLA
in infected cells that become responsive to antigen after HCV
therapy and its subsequent reversion to the anergic state after
CD8 T-cell depletion might be governed by the production of
a suppressive cytokine such as IL-10. Finally, reduced expres-
sion of both T-bet and GATA-3 from infected cells and ele-
vated levels of these transcription factors in CD4 T splenic T
cells of cured mice confirmed expansion of Leishmania-reac-
tive Th1 and Th2 clones. In fact, elevated levels of GATA-3, a
master transcriptional regulator of the IL-4 and IL-13 locus
from CD4 T cells, corroborated well with increased IL-4 and
IL-13 production in HCV-treated mice. Importantly, in light of
a recent report that suggested the failure of GATA-3 to reg-
ulate transcriptional activity of IL-10 gene in vivo (39), tran-
scription of IL-10 might not be contingent on the GATA-3
activity of Th2 cells if the principle source of IL-10 is from a
discrete population of CD4 T-cell subset. Further studies are
required to distinguish between the contributory roles of IL-4-
and IL-13-producing Th and IL-10-producing Treg cells in
infection- and vaccine-induced immune response.
Early studies in both mice (17) and humans (18) suggested
that cure was independent of the differential production of Th1
and Th2 cytokines. Although IFN- has been universally re-
garded as a host-protective cytokine in both CL and VL, a
disease-promoting role for an IL-4- and IL-13-associated Th2
response in VL has not been demonstrated. Consequently,
studies in B6/129 (36) and BALB/c (42) mice have shown that
IL-4- and IL-4R-deficient animals are in fact more suscepti-
ble to disease than their wild-type counterparts. In addition,
not only is IL-4 and IL-4R signaling essential for optimal
clearance of L. donovani from the liver (42), it is also essential
for effective T-cell-dependent chemotherapy (2) and vaccine-
induced resistance mediated by CD8 T cells (41). In the
absence of IL-4, an IFN--producing Th1 response cannot be
maintained after chemotherapy or cannot be induced by vac-
cination. Hence, additionally beneficial, protective roles for
IL-4 and IL-13, along with IFN-, in L. donovani infection
cannot be discounted. Furthermore, a cure in susceptible
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BALB/c mice is largely dependent on IL-12 that promotes the
expansion of both the Th2 and the Th1 response (10). As
several studies have suggested, a protective influence for IL-4
and IL-13 in leishmaniasis, as well as beneficial roles for IL-4
and IL-13, along with IFN-, in L. donovani infection, cannot
be discounted (2, 36, 41). Although these data indicate that the
essential effector mechanism of HCV is mediated by CD8 T
cells, this doesn’t exclude the beneficial role of CD4 T cells.
CD8 CTL activation by CD4 T cells can also be vital, since
CD4 T cell help has been shown to be required at the priming
phase of CTLs (38).
The present study has shown that hybrid cell therapy capable
of generating a vigorous antigen-specific CD8 CTL response
by exploiting the allogeneic MHC response can be imple-
mented in future vaccine designs against an advanced state of
VL. Successful application of HCV in this infectious disease
model opens up an avenue for its future use as a combined
therapeutic approach against multiple infectious diseases with
defined immunodominant antigens.
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